The guiding principle of our business is to deliver reliable and effective products of the highest quality, so every drug distributed by Interlux is carefully tested and tracked at various stages of its life cycle. The Company's Pharmacovigilance Group monitors the safety of medicines for which we are marketing authorization holders. The Monitoring Group shall also:
- identifies new potential risks that may affect the quality, safety and efficacy of the medicinal product;
- evaluates the balance between the risks and the benefits of using the medicine;
- provides up-to-date information on the safety of medicines to doctors, pharmacists, patients and partners.
SIA “Interlux” receives information on the safety of the use of medicines from doctors, pharmacists, other healthcare professionals, partners and patients. We will carefully evaluate this and, if necessary, report it to the European Medicines Agency's (EMA) Eudravigilance database. We will also provide information to other competent authorities in the field of pharmacovigilance and to the manufacturers, as appropriate.
Patients, their relatives, doctors, pharmacists and any other interested party can and are kindly invited to report any side effects of the medicine distributed by SIA “Interlux” by e-mail firstname.lastname@example.org, as well as by phone: (+371) 67795240 ( during working hours) or (+371) 29115221 (24 hours a day).
Reporting will provide you with information about the processing and storage of your personal data.
Natalija Utkina, Mg.sc.med.
Deputy Person Responsible for Pharmacovigilance